Consistent with this report, our study has shown that CDK4/6 inhibition can sensitize TNBC cancer cells to PI3K inhibition, producing a greater reduction of cell viability in an RB-dependent and subtype-independent manner39,40. The gene discussed is CDK4; the disease is cancer.